Strategies for antiviral screening targeting early steps of virus infection

Virologica Sinica

Volumn 25, Issue 4, 2010, Pages 281-293

  Peng, Tao ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Antiviral therapeutics; Inhibitor screening; Virus infection; Virus life cycle

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; HEPATITIS C VACCINE; LUCIFERASE; P SELECTIN GLYCOPROTEIN LIGAND 1; PEGINTERFERON; RIBAVIRIN; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS RNA;

CELL FUSION; DRUG SCREENING; DRUG TARGETING; ENTEROVIRUS 71; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEMBRANE FUSION; MICROBIAL ACTIVITY; NONHUMAN; PROMOTER REGION; PROTEIN CONFORMATION; REPORTER GENE; RETROVIRUS; REVIEW; UNSPECIFIED SIDE EFFECT; VIROGENESIS; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; ENTEROVIRUS A, HUMAN; HEPACIVIRUS; HUMANS; SIMPLEXVIRUS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS; HUMAN ENTEROVIRUS 71; SIMPLEXVIRUS;

EID: 77956534674     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-010-3135-z     Document Type: Review

References (86)

1. Agnello V, Abel G, Elfahal M, et al. 1999. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA, 96:12766-12771.
2. Arduino P G, Porter S R. 2008. Herpes Simplex Virus Type 1 infection: overview on relevant clinicopathological features. J Oral Pathol Med, 37:107-121.
3. Atanasiu D, Whitbeck J C, de Leon MP, et al.. 2010. Bimolecular complementation defines functional regions of HSV gB that are involved with gH/gL as necessary steps leading to cell fusion. J Virol, 84:3825-3834.
4. Banerjee M, Khayat R, Walukiewicz H E, et al. 2009. Dissecting the functional domains of a nonenveloped virus membrane penetration peptide. J Virol, 83:6929-6933.
5. Barth H, Schafer C, Adah M I, et al. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem, 278:41003-41012.
6. Bartosch B, Cosset F L. 2006. Cell entry of hepatitis C virus. Virology, 348:1-12.
7. Basu A, Kanda T, Beyene A, et al. 2007. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol, 81:3933-3941.
8. Bender F C, Whitbeck J C, Lou H, et al. 2005. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol, 79:11588-11597.
9. Bertaux C, Dragic T. 2006. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol, 80:4940-4948.
10. Bevilacqua F, Marcello A, Toni M, et al. 1991. Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient. J Acquir Immune Defic Syndr, 4:967-969.
11. Brandenburg B, Lee L Y, Lakadamyali M, et al. 2007. Imaging poliovirus entry in live cells. PLoS Biol, 5: e183.
12. Budkowska A. 2009. Mechanism of cell infection with hepatitis C virus (HCV)-a new paradigm in virus-cell interaction. Pol J Microbiol, 58:93-98.
13. Burlone M E, Budkowska A. 2009. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol, 90:1055-1070.
14. Campadelli-Fiume G, Amasio M, Avitabile E, et al. 2007. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol, 17:313-326.
15. Chandran K, Farsetta D L, Nibert M L. 2002. Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption. J Virol, 76:9920-9933.
16. Codran A, Royer C, Jaeck D, et al. 2006. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol, 87:2583-2593.
17. Cole N L, Grose C. 2003. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev Med Virol, 13:207-222.
18. De Clercq E. 2004. Antiviral drugs in current clinical use. J Clin Virol, 30:115-133.
19. Dicker I B, Blasecki J W, Seetharam S. 1995. Herpes simplex type1:lacZ recombinant viruses. II. Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle. Antiviral Res, 28:213-224.
20. Dreux M, Dao Thi V L, Fresquet J, et al. 2009. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intraand extra-cellular domains. PLoS Pathog, 5: e1000310.
21. Duan R, de Vries R D, Osterhaus A D, et al. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis, 198:659-663.
22. Dubuisson J, Helle F, Cocquerel L. 2008. Early steps of the hepatitis C virus life cycle. Cell Microbiol, 10:821-827.
23. Falanga A, Cantisani M, Pedone C, et al. 2009. Membrane fusion and fission: enveloped viruses. Protein Pept Lett, 16:751-759.
24. Falconer M M, Gilbert J M, Roper A M, et al. 1995. Rotavirus-induced fusion from without in tissue culture cells. J Virol, 69:5582-5591.
25. Feng Z H, Wang Q C, Nie Q H, et al. 2004. DC-SIGN: binding receptor for HCV? World J Gastroenterol, 10:925-929.
26. Field H, McMillan A, Darby G. 1981. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis, 143:281-285.
27. Garner J A. 2003. Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv Drug Deliv Rev, 55:1497-1513.
28. Ghukasyan V, Hsu Y Y, Kung S H, et al. 2007. Application of fluorescence resonance energy transfer resolved by fluorescence lifetime imaging microscopy for the detection of enterovirus 71 infection in cells. J Biomed Opt, 12:1-8.
29. Grondin B, De Luca N. 2000. Herpes simplex virus type 1 ICP4 promotes transcription preinitiation complex formation by enhancing the binding of TFIID to DNA. J Virol, 74:11504-11510.
30. Heo H T. 2008. A potential role of the heparan sulfate in the hepatitis C virus attachment. Acta Virol, 52:7-15.
31. Han Q, Xu C, Wu C, et al. 2009. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res, 145:63-73.
32. Hannah B P, Cairns T M, Bender F C, et al. 2009. Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol, 83:6825-6836.
33. Heldwein E E, Krummenacher C. 2008. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci, 65:1653-1668.
34. Helle F, Dubuisson J. 2008. Hepatitis C virus entry into host cells. Cell Mol Life Sci, 65:100-112. (Pubitemid 351152228)
35. Hsu M, Zhang J, Flint M, et al. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA, 100:7271-7276.
36. Iro M, Witteveldt J, Angus A G, et al. 2009. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res, 83:148-155.
37. Kalia M, Jameel S. 2009. Virus entry paradigms. Amino Acids, DOI: 10.1007/s00726-009-0363-3.
38. Koutsoudakis G, Kaul A, Steinmann E, et al. 2006. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol, 80:5308-5320.
39. Laquerre S, Argnani R, Anderson D B, et al. 1998. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cellto-cell spread. J Virol, 72:6119-6130.
40. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int, 29 Suppl 1:74-81.
41. Lavillette D, Bartosch B, Nourrisson D, et al. 2006. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem, 281:3909-3917.
42. Lee J C, Shih Y F, Hsu S P, et al. 2003. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal Biochem, 316:162-170.
43. Lee J C, Yu M C, Lien T W, et al. 2005. Highthroughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. Assay Drug Dev Technol, 3:385-392.
44. Leung W C. 1980. Cooperation between herpes simplex virus specific alpha protein and host cell RNA polymerase II in the transcription of viral deoxypyrimidine kinase. Can J Microbiol, 26:401-404.
45. Liu Y X, Xie J J, He Y X, et al. 2008. [Study of the clinical and laboratory features of hand-foot-mouth disease]. Chinese J Exp Clin Virol, 22:475-477.
46. Lozach P Y, Amara A, Bartosch B, et al. 2004. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem, 279:32035-45.
47. Ludwig I S, Lekkerkerker A N, Depla E, et al. 2004. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol, 78:8322-8332.
48. Madan R P, Mesquita P M, Cheshenko N, et al. 2007. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol, 81:7636-7646.
49. Mann A M, Rusert P, Berlinger L, et al. 2009. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23:1659-1667.
50. Morfin F, Thouvenot D. 2003. Herpes simplex virus resistance to antiviral drugs. J Clin Virol, 26:29-37.
51. Morikawa K, Zhao Z, Date T, et al. 2007. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol, 79:714-723.
52. Mudhakir D, Harashima H. 2009. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J, 11:65-77.
53. Netski D M, Mosbruger T, Depla E, et al. 2005. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis, 41:667-675.
54. Nishimura Y, Shimojima M, Tano Y, et al. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med, 15:794-797.
55. O'Donnell C D, Tiwari V, Oh M J, et al. 2006. A role for heparan sulfate 3-O-sulfotransferase isoform 2 in herpes simplex virus type 1 entry and spread. Virology, 346:452-459. (Pubitemid 43357888)
56. Ortner B, Huang C W, Schmid D, et al. 2009. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol, 81:317-324.
57. Owsianka A M, Timms J M, Tarr A W, et al. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol, 80:8695-704.
58. Patel K P, Bergelson J M. 2009. Receptors identified for hand, foot and mouth virus. Nat Med, 15:728-729.
59. Pietschmann T, Kaul A, Koutsoudakis G, et al. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA, 103:7408-7413.
60. Ploss A, Evans M J, Gaysinskaya V A, et al. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886.
61. Popescu C I, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell, 102:63-74.
62. Rajcani J, Vojvodova A. 1998. The role of herpes simplex virus glycoproteins in the virus replication cycle. Acta Virol, 42:103-118.
63. Ranganathan S, Singh S, Poh C L, et al. 2002. The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics, 1:43-52.
64. Reske A, Pollara G, Krummenacher C, et al. 2007. Understanding HSV-1 entry glycoproteins. Rev Med Virol, 17:205-215.
65. Schinazi R F, Nahmias A J. 1982. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. Am J Med, 73:40-48.
66. Schwarz A K, Grove J, Hu K, et al. 2009. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol, 83:12407-12414.
67. Smith J S, Robinson N J. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis, 186 Suppl 1: S3-28.
68. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol, 6:401-410.
69. Stranska R, Schuurman R, Scholl D R, et al. 2004. ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing. Antimicrob Agents Chemother, 48:2331-2333.
70. Tanaka M, Kodaira H, Nishiyama Y, et al. 2004. Construction of recombinant herpes simplex virus type I expressing green fluorescent protein without loss of any viral genes. Microbes Infect, 6:485-493.
71. Tani H, Komoda Y, Matsuo E, et al. 2007. Replication competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol, 81:8601-8612.
72. Taylor T J, Knipe D M. 2009. The use of green fluorescent fusion proteins to monitor herpes simplex virus replication. Methods Mol Biol, 515:239-248.
73. Trybala E, Liljeqvist J A, Svennerholm B, et al. 2000. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J Virol, 74:9106-9114.
74. Tscherne D M, Jones C T, Evans M J, et al. 2006. Timeand temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol, 80:1734-1741.
75. Wang Q C, Feng Z H, Nie Q H, et al. 2004. DC-SIGN: binding receptors for hepatitis C virus. Chin Med J (Engl), 117:1395-1400.
76. Wang S M, Ho T S, Shen C F, et al. 2008. Enterovirus 71, one virus and many stories. Pediatr Neonatol, 49:113-115.
77. Wang Y C, Kao C L, Liu W T, et al. 2002. A cell line that secretes inducibly a reporter protein for monitoring herpes simplex virus infection and drug susceptibility. J Med Virol, 68:599-605.
78. Whidby J, Mateu G, Scarborough H, et al. 2009. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol, 83:11078-11089.
79. Wright C C, Wisner T W, Hannah B P, et al. 2009. Fusion between perinuclear virions and the outer nuclear membrane requires the fusogenic activity of herpes simplex virus gB. J Virol, 83:11847-11856.
80. Wymer J P, Chung T D, Chang Y N, et al. 1989. Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J Virol, 63:2773-2784.
81. Yamayoshi S, Yamashita Y, Li J, et al. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med, 15:798-801.
82. Yang B, Chuang H, Yang K D. 2009. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J, 6:141.
83. Zahn A, Allain J P. 2005. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol, 86:677-685.
84. Zeisel M B, Barth H, Schuster C, et al. 2009. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci, 14:3274-3285.
85. Zeisel M B, Baumert T F. 2009. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol, 4:511-517.
86. Ziegler S, Kronenberger B, Albrecht B A, et al. 2009. Development and evaluation of a FACS-based medium throughput assay for HCV entry inhibitors. J Biomol Screen, 14:620-626.